| Safety of the BNT162b2 COVID-19 vaccine in children aged 5 to 17 years M Hu, HL Wong, Y Feng, PC Lloyd, ER Smith, KL Amend, A Kline, ... JAMA pediatrics 177 (7), 710-717, 2023 | 13 | 2023 |
| Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years PC Lloyd, M Hu, HL Wong, A Shoaibi, CK Zhou, AC Lo, K Amend, ... Vaccine 40 (45), 6481-6488, 2022 | 10 | 2022 |
| Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US Children Aged 6 Months to 17 Years M Hu, A Shoaibi, Y Feng, PC Lloyd, HL Wong, ER Smith, KL Amend, ... JAMA Network Open 7 (4), e248192-e248192, 2024 | 1 | 2024 |
| Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children aged 5-17 years M Hu, HL Wong, Y Feng, PC Lloyd, ER Smith, KL Amend, A Kline, ... medRxiv, 2022.10. 28.22281532, 2022 | 1 | 2022 |
| Recommendations for Prevention and Control of Infections in Neonatal Intensive Care Unit Patients: Staphylococcus aureus (2020): Guideline: NICU–S. aureus AM Milstone, A Elward, MT Brady, K Cox | 1 | 2020 |
| Safety of Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID-19 Vaccines in US Children Aged 6 months to 17 years M Hu, A Shoaibi, Y Feng, PC Lloyd, HL Wong, ER Smith, KL Amend, ... | | 2023 |
| Safety of Monovalent BNT162b2 (Pfizer–BioNTech), mRNA–1273 (Moderna), and NVX–CoV2373 (Novavax) COVID–19 Vaccines in US Children Aged 6 months to 17 years PC Lloyd, M Hu, A Shoaibi, Y Feng, HL Wong, ER Smith, KL Amend, ... medRxiv, 2023.10. 13.23296903, 2023 | | 2023 |
| Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children aged 5-17 years (preprint) M Hu, HL Wong, Y Feng, PC Lloyd, ER Smith, KL Amend, A Kline, ... | | 2022 |
| Arizona’s Mentally Ill and Their Use of the Emergency Department C Harris Walden University, 2017 | | 2017 |
